share_log

Institutional Investors in Vera Therapeutics, Inc. (NASDAQ:VERA) Lost 9.3% Last Week but Have Reaped the Benefits of Longer-term Growth

Institutional Investors in Vera Therapeutics, Inc. (NASDAQ:VERA) Lost 9.3% Last Week but Have Reaped the Benefits of Longer-term Growth

Vera Therapeutics, Inc.(納斯達克股票代碼:VERA)的機構投資者上週下跌了9.3%,但已經從長期增長中受益
Simply Wall St ·  05/13 21:17

Key Insights

關鍵見解

  • Significantly high institutional ownership implies Vera Therapeutics' stock price is sensitive to their trading actions
  • A total of 9 investors have a majority stake in the company with 52% ownership
  • Insiders have sold recently
  • 高機構所有權意味着Vera Therapeutics的股價對其交易行爲很敏感
  • 共有9名投資者擁有該公司的多數股權,擁有52%的所有權
  • 業內人士最近賣出了

A look at the shareholders of Vera Therapeutics, Inc. (NASDAQ:VERA) can tell us which group is most powerful. With 62% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).

看看Vera Therapeutics, Inc.(納斯達克股票代碼:VERA)的股東可以告訴我們哪個集團最強大。機構擁有62%的股份,是公司的最大股份。換句話說,該集團面臨最大的上行潛力(或下行風險)。

Institutional investors endured the highest losses after the company's market cap fell by US$219m last week. Still, the 418% one-year gains may have helped mitigate their overall losses. But they would probably be wary of future losses.

上週該公司的市值下降2.19億美元后,機構投資者遭受了最大的損失。儘管如此,418%的一年期漲幅可能有助於減輕他們的總體虧損。但是他們可能會對未來的損失保持警惕。

In the chart below, we zoom in on the different ownership groups of Vera Therapeutics.

在下圖中,我們放大了Vera Therapeutics的不同所有權群體。

ownership-breakdown
NasdaqGM:VERA Ownership Breakdown May 13th 2024
納斯達克通用汽車:VERA 所有權明細 2024 年 5 月 13 日

What Does The Institutional Ownership Tell Us About Vera Therapeutics?

關於Vera Therapeutics,機構所有權告訴我們什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見指數的回報進行比較。因此,他們通常會考慮收購相關基準指數中包含的大型公司。

As you can see, institutional investors have a fair amount of stake in Vera Therapeutics. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Vera Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.

如你所見,機構投資者持有Vera Therapeutics的大量股份。這意味着在這些機構工作的分析師已經看過這隻股票,他們很喜歡。但是就像其他人一樣,他們可能錯了。當多家機構擁有一隻股票時,總是存在處於 “擁擠交易” 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到Vera Therapeutics的歷史收益和收入,但請記住,故事總是有更多內容。

earnings-and-revenue-growth
NasdaqGM:VERA Earnings and Revenue Growth May 13th 2024
納斯達克通用汽車公司:VERA 收益和收入增長 2024 年 5 月 13 日

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Our data indicates that hedge funds own 8.0% of Vera Therapeutics. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Longitude Capital Management Co., LLC is currently the largest shareholder, with 9.4% of shares outstanding. Commodore Capital LP is the second largest shareholder owning 8.1% of common stock, and Kynam Capital Management, LP holds about 6.7% of the company stock.

投資者應注意,機構實際上擁有公司一半以上的股份,因此它們可以共同行使巨大的權力。我們的數據顯示,對沖基金擁有Vera Therapeutics8.0%的股份。這引起了我的注意,因爲對沖基金有時會試圖影響管理層,或者帶來能夠爲股東創造短期價值的變革。經緯資本管理有限公司目前是最大股東,已發行股份的9.4%。Commodore Capital LP是第二大股東,擁有8.1%的普通股,Kynam Capital Management, LP持有該公司約6.7%的股份。

We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

我們還觀察到,前9名股東佔股票登記冊的一半以上,少數規模較小的股東可以在一定程度上平衡大股東的利益。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。有不少分析師報道了該股,因此你可以很容易地研究預測的增長。

Insider Ownership Of Vera Therapeutics

維拉療法的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

不同國家對內部人員的定義可能略有不同,但董事會成員總是計算在內。公司管理層經營業務,但首席執行官將向董事會負責,即使他或她是董事會成員。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。

Our most recent data indicates that insiders own less than 1% of Vera Therapeutics, Inc.. But they may have an indirect interest through a corporate structure that we haven't picked up on. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around US$13m worth of shares (at current prices). It is good to see board members owning shares, but it might be worth checking if those insiders have been buying.

我們的最新數據顯示,內部人士擁有的Vera Therapeutics, Inc.不到1%的股份。但是,他們可能會通過我們尚未採用的公司結構獲得間接利益。這是一家相當大的公司,因此董事會成員有可能在不擁有太多比例權益的情況下擁有該公司的有意義的權益。在這種情況下,他們擁有價值約1300萬美元的股票(按當前價格計算)。很高興看到董事會成員擁有股票,但可能值得檢查一下這些內部人士是否在買入。

General Public Ownership

一般公有制

With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Vera Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Vera Therapeutics擁有11%的所有權,主要由個人投資者組成的公衆對Vera Therapeutics有一定程度的影響力。這種所有權規模雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。

Private Equity Ownership

私募股權所有權

With a stake of 15%, private equity firms could influence the Vera Therapeutics board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

私募股權公司持有15%的股份,可能會影響Vera Therapeutics的董事會。有時我們會看到私募股權長期存在,但總的來說,它們的投資期限較短,而且顧名思義,對上市公司的投資並不多。一段時間後,他們可能會考慮出售資本並將其重新部署到其他地方。

Private Company Ownership

私人公司所有權

We can see that Private Companies own 3.5%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們可以看到,私人公司擁有已發行股份的3.5%。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

It's always worth thinking about the different groups who own shares in a company. But to understand Vera Therapeutics better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Vera Therapeutics you should be aware of, and 1 of them is concerning.

擁有公司股份的不同群體總是值得考慮的。但是,爲了更好地了解Vera Therapeutics,我們需要考慮許多其他因素。一個很好的例子:我們發現了你應該注意的4個Vera Therapeutics警告信號,其中一個令人擔憂。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一樣,你可能需要考慮這家公司是會成長還是會萎縮。幸運的是,您可以查看這份免費報告,其中顯示了分析師對其未來的預測。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論